Morpholino

MO3-sulf2a

ID
ZDB-MRPHLNO-210215-1
Name
MO3-sulf2a
Previous Names
  • sulf2aMOsplice (1)
Target
Sequence
5' - GAAACTATACTGTGACCCACTCTTC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO3-sulf2a
Phenotype
Phenotype resulting from MO3-sulf2a
Phenotype of all Fish created by or utilizing MO3-sulf2a
Phenotype Fish Conditions Figures
spinal cord interneuron sim1a expression increased amount, abnormal WT + MO3-sulf2a standard conditions Figure 2 with image from Danesin et al., 2021
spinal cord interneuron cell fate specification increased occurrence, abnormal WT + MO3-sulf2a standard conditions Figure 2 with image from Danesin et al., 2021
spinal cord interneuron increased amount, abnormal WT + MO3-sulf2a standard conditions Figure 2 with image from Danesin et al., 2021
spinal cord olig2 expression decreased amount, abnormal vu17Tg + MO3-sulf2a control Figure 5 with image from Danesin et al., 2021
spinal cord motor neuron olig2 expression decreased amount, abnormal vu17Tg + MO3-sulf2a control Figure 4 with image from Danesin et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal vu17Tg + MO3-sulf2a control Figure 4 with image from Danesin et al., 2021
spinal cord interneuron cell fate specification increased occurrence, abnormal vu17Tg + MO3-sulf2a control Figure 4 with image from Danesin et al., 2021
oligodendrocyte cell fate specification decreased occurrence, abnormal vu17Tg + MO3-sulf2a control Figure 4 with image from Danesin et al., 2021
spinal cord interneuron increased amount, abnormal vu17Tg + MO3-sulf2a control Figure 4 with image from Danesin et al., 2021
oligodendrocyte cell fate specification decreased occurrence, abnormal vu19Tg + MO3-sulf2a standard conditions Figure 3 with image from Danesin et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal vu19Tg + MO3-sulf2a standard conditions Figure 3 with image from Danesin et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal vu17Tg; vu19Tg + MO3-sulf2a standard conditions Figure 6 with image from Danesin et al., 2021
oligodendrocyte cell fate specification decreased occurrence, abnormal vu17Tg; vu19Tg + MO3-sulf2a standard conditions Figure 6 with image from Danesin et al., 2021
Citations